Veridian Research

Compare · Research-Use-Only

Ipamorelin vs Ipamorelin / CJC-1295

Ipamorelin alone produces a clean GH pulse without elevating cortisol or prolactin. The Ipamorelin / CJC-1295 combination pairs that pulse with CJC-1295's extended half-life for sustained GH/IGF-1 elevation in research protocols.

Specification
Ipamorelin
Ipamorelin / CJC-1295
Class
Synthetic peptide
Synthetic peptide
Molecular weight
711.85 Da
711.85 Da (ipamorelin) / 3367.97 Da (CJC-1295 no-DAC)
Sequence
Aib-His-D-2Nal-D-Phe-Lys-NH2
Aib-His-D-2Nal-D-Phe-Lys-NH2 (ipamorelin); Modified GHRH(1-29) (CJC-1295)
Purity
>=99%
>=99%
Form
Lyophilized powder
Lyophilized powder
CAS number
170851-70-4
170851-70-4 (ipamorelin)

Ipamorelin

Ipamorelin is a selective growth hormone secretagogue pentapeptide that acts as a partial agonist at the ghrelin receptor (GHS-R1a), stimulating pulsatile GH release from pituitary somatotrophs. Unlike older GH secretagogues, ipamorelin demonstrates high selectivity with minimal effects on ACTH, cortisol, aldosterone, or prolactin.

Ipamorelin / CJC-1295

This combination targets two distinct but synergistic nodes in the growth hormone (GH) axis. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH(1–29)) incorporating four amino acid substitutions that confer DPP-4 resistance, extending half-life. The non-DAC version (also known as mod-GRF(1–29)) has a half-life of ~30 minutes, while the DAC (Drug Affinity Complex) version — which covalently binds to plasma albumin via a maleimide linker — has a half-life of approximately 6–8 days, enabling once or twice-weekly dosing. CJC-1295 acts on the GHRH receptor (GHRHR) on pituitary somatotrophs, increasing GH pulse amplitude. Ipamorelin is a selective growth hormone secretagogue pentapeptide that acts as a partial agonist at the ghrelin receptor (GHS-R1a), increasing GH pulse frequency via a distinct intracellular pathway (Gq/PKC rather than Gs/cAMP). Critically, ipamorelin demonstrates high receptor selectivity — it does not appreciably stimulate ACTH, cortisol, or aldosterone release at research doses, unlike older GH secretagogues (GHRP-6, GHRP-2). The synergistic co-administration of CJC-1295 (amplitude) and ipamorelin (frequency) produces GH release patterns that more closely mimic youthful physiological pulsatility and has been shown in preclinical and small human studies to amplify GH and IGF-1 more than either agent alone.

Other research peptide comparisons

Both compounds in stock at Veridian. 99%+ HPLC purity, same-day US shipping.

Browse all research peptides →